Moderna (NASDAQ:MRNA – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Institutional & Insider Ownership
75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Moderna and Insmed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moderna | 4 | 15 | 6 | 0 | 2.08 |
| Insmed | 1 | 1 | 23 | 1 | 2.92 |
Moderna currently has a consensus price target of $107.10, suggesting a potential downside of 51.71%. Insmed has a consensus price target of $196.52, suggesting a potential upside of 77.54%. Given Insmed’s stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Moderna.
Profitability
This table compares Moderna and Insmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moderna | -141.43% | -28.30% | -19.39% |
| Insmed | -39.85% | -96.38% | -32.55% |
Risk and Volatility
Moderna has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Valuation & Earnings
This table compares Moderna and Insmed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moderna | $1.94 billion | 45.55 | -$2.82 billion | ($7.99) | -27.76 |
| Insmed | $606.42 million | 40.04 | -$1.28 billion | ($2.82) | -39.25 |
Insmed has lower revenue, but higher earnings than Moderna. Insmed is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Summary
Moderna beats Insmed on 8 of the 15 factors compared between the two stocks.
About Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
